OptiBiotix Health inks licencing agreement with Kappa Bioscience

Writer, Stock Market Wire
Monday, July 1, 2019 - 08:51

OptiBiotix Health said subsidiary ProBiotix Health had signed a license agreement with Kappa Bioscience.

The agreement covered the use of OptiBiotix Health's blood pressure-reducing probiotic strain Lactobacillus plantarum in a new application area within cardiovascular health.

It covered 27 countries, largely in Europe, but also included Russia and Singapore.=

At 8:51am: (LON:OPTI) Optibiotix Health Plc share price was +1p at 85p


Related content

OptiBiotix Health gets key validation for probiotic product

OptiBiotix Health said subsidiary ProBiotix Health had completed process validation under pharmaceutical good manufacturing practices for its probiotic product as a drug substance.

The company...

Wed, 09/10/2019 - 07:33


OptiBiotix Health inks distribution pact for South Africa, neighbouring countries

OptiBiotix Health said it had entered into a one-year exclusive distribution agreement with a South African partner for its consumer weight-management products in South Africa...

Wed, 18/09/2019 - 07:48


OptiBiotix Health books first-half loss as it inks more distribution pacts

Dietry supplement group for weight loss and cholesterol control OptiBiotix Health booked a first-half loss after modest sales were offset by administrative costs.

Pre-tax losses...

Wed, 28/08/2019 - 08:01


OptiBiotix Health inks distribution pact in Australia, NZ with Maxum Foods

OptiBiotix Health said it had entered into a manufacturing, supply and distribution agreement with Maxum Foods for its weight management technology in Australia and New...

Mon, 12/08/2019 - 08:01


OptiBiotix Health inks license agreement with Tenshindo in Japan

OptiBiotix Health said subsidiary ProBiotix Health had signed a non-exclusive license agreement with Tenshindo for the use of Lactobacillus plantarum in cardiovascular food supplements in...

Wed, 03/07/2019 - 07:54